Found: 8
Select item for more details and to access through your institution.
A Randomized, Single‐dose, Phase I Clinical Comparison of a Trastuzumab Biosimilar With a Reference Trastuzumab Formulation in Healthy Chinese Male Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 181, doi. 10.1002/cpdd.1189
- By:
- Publication type:
- Article
A Randomized, Double‐Blind, Parallel Controlled, Single‐Dose Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of the Infliximab Biosimilar CMAB008 and the Reference Product in Healthy Chinese Male Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 9, p. 1028, doi. 10.1002/cpdd.1135
- By:
- Publication type:
- Article
Improving product quality and productivity of an antibody-based biotherapeutic using inverted frustoconical shaking bioreactors.
- Published in:
- Frontiers in Bioengineering & Biotechnology, 2024, p. 1, doi. 10.3389/fbioe.2024.1352098
- By:
- Publication type:
- Article
Structural basis of immunosuppression by the therapeutic antibody daclizumab.
- Published in:
- Cell Research, 2010, v. 20, n. 12, p. 1361, doi. 10.1038/cr.2010.130
- By:
- Publication type:
- Article
Quantitative analysis of histone H3 and H4 post-translational modifications in doxorubicin-resistant leukemia cells.
- Published in:
- Biomedical Chromatography, 2016, v. 30, n. 4, p. 638, doi. 10.1002/bmc.3608
- By:
- Publication type:
- Article
Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system.
- Published in:
- Drug Design, Development & Therapy, 2019, v. 13, p. 791, doi. 10.2147/dddt.s170913
- By:
- Publication type:
- Article
A novel glycosylated anti-CD20 monoclonal antibody from transgenic cattle.
- Published in:
- Scientific Reports, 2018, v. 8, n. 1, p. 1, doi. 10.1038/s41598-018-31417-2
- By:
- Publication type:
- Article
Population Pharmacokinetics of CMAB008 (an Infliximab Biosimilar) and Remicade<sup>®</sup> in Healthy Subjects and Patients with Moderately to Severely Active Rheumatoid Arthritis.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 3, p. 1005, doi. 10.1007/s12325-022-02396-8
- By:
- Publication type:
- Article